An Open Label, Comparative, Multi-Center Study, to Evaluate the Efficacy and Safety of Peginterferon Alfa-2a Plus Ribavirin in the Treatment of Patients With Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis B; Hepatitis C
- Focus Therapeutic Use
- 13 Oct 2009 Planned end date changed from 1 Aug 2007 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 13 Oct 2009 Planned end date changed from 1 Aug 2007 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 19 Nov 2005 New trial record.